Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects
Open Access
- 27 November 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 9, 2888
- https://doi.org/10.3389/fmicb.2018.02888
Abstract
Carbapenem-resistant Enterobacteriaceae (CRE), a major resistance concern emerging during the last decade because of significantly compromising the efficacy of carbapenem agents, has currently become an important focus of infection control. Many investigations have shown a high association of CRE infections with high case-fatality rates. In Taiwan, a few surveys observed that a significant proportion (29–47%) of the CR-Klebsiella pneumoniae isolates harbored a plasmidic allele encoding K. pneumoniae carbapenemases (KPC, especially KPC-2). A significant increase in the number of oxacillinase (OXA)-48-like carbapenemases among CR-K. pneumoniae isolates was observed between 2012 and 2015. By striking contrast, isolates of CR-Escherichia coli and CR-Enterobacter species in Taiwan had a much lower percentage of carbapenemase production than CR-K. pneumoniae isolates. This differs from isolates found in China as well as in the India subcontinent. Apart from the hospital setting, CRE was also cultured from the inpatients from communities or long-term care facilities (LTCF). Therefore, implementation of regular CRE screening of LTCF residents, strict disinfectant use in nursing homes and hospital settings, and appropriate control of antibiotic prescriptions is suggested to alleviate the spread of clinical CRE isolates in Taiwan. Although there are some promising new antibiotics against CRE, such as ceftazidime-avibactam, meropenem-vaborbactam, aztreonam-avibactam and cefiderocol, these agents are not available in Taiwan currently. Therefore, in order to effectively decrease case-fatality rates among patients with the infections owing to carbapenemase-producing CRE isolates, combination antibiotic schemes, including colistin (or amikacin) and/or tigecycline in combination with an anti-pseudomonal carbapenem agent, remain the mainstay for treating clinical CRE infections.This publication has 79 references indexed in Scilit:
- Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination TherapyClinical Infectious Diseases, 2012
- The Combination of Doripenem and Colistin Is Bactericidal and Synergistic against Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2012
- Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial RegimensAntimicrobial Agents and Chemotherapy, 2012
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of PatientsAntimicrobial Agents and Chemotherapy, 2011
- Efficacy and safety of tigecycline: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2011
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyThe Lancet Infectious Diseases, 2010
- In Vitro Activity of Fosfomycin against bla(KPC)-Containing Klebsiella pneumoniae Isolates, Including Those Nonsusceptible to Tigecycline and/or ColistinAntimicrobial Agents and Chemotherapy, 2009
- Isolation of Imipenem-Resistant Enterobacter Species: Emergence of KPC-2 Carbapenemase, Molecular Characterization, Epidemiology, and OutcomesAntimicrobial Agents and Chemotherapy, 2008
- Genetic Structures at the Origin of Acquisition of the β-Lactamase bla KPC GeneAntimicrobial Agents and Chemotherapy, 2008
- Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo-β-Lactamase-Producing Enterobacteriaceae : Report from the SENTRY Antimicrobial Surveillance ProgramAntimicrobial Agents and Chemotherapy, 2008